STABILIZED VARIANTS OF STREPTOMYCES SUBTILISIN INHIBITOR

Abstract: The present invention relates to variants of Streptomyces subtilisin inhibitor (SSI) and those inhibitors having homology to SSI. Such variants are useful in conjunction with enzymes, particularly proteases, in cleaning compositions and personal care compositions. The variants comprise an amino acid substitution at position 63 corresponding to SSI. Such variants provide greater proteolytic stability in cleaning compositions and personal care compositions. The present invention also relates to cleaning compositions and personal care compositions comprising the present variants, as well as genes encoding the variants.

Description: STABILIZED VARIANTS OF STREPTOMYCES SUBTILISLN INHIBITOR CROSS REFERENCE TO RELATED APPLICATION This application claims the benefit of U.S. Provisional Application No. 60/091,911, filed July 7, 1998. FIELD OF THE INVENTION The present invention relates to variants of Streptomyces subtilisin inhibitor (SSI) and those inhibitors having homology to SSI (SSI-like inhibitors). Such variants are useful in conjunction with enzymes, particularly proteases, in cleaning compositions and- personal care compositions. The present invention also relates to cleaning compositions and personal care compositions comprising the present variants, as well as genes encoding the variants. BACKGROUND OF THE INVENTION Enzymes make up the largest class of naturally occurring proteins. One class of enzyme includes proteases which catalyze the hydrolysis of other proteins. This ability to hydrolyze proteins has been exploited by incorporating naturally occurring and protein engineered proteases into cleaning compositions, particularly those relevant to laundry applications. Furthermore, although explored to a lesser extent, others have incorporated such proteases into personal care compositions. During storage of the composition or even expression of the protease, however, the protease is frequently degraded by itself or may degrade other enzymes present in the composition. As a result of this degradation, the cleaning and personal care compositions have limited ability to achieve the intended enhanced performance. It would therefore be beneficial to incorporate into the compositions an inhibitor of protease activity to limit protease autolysis and other degradation. It would be advantageous to provide reversible inhibitors of the protease, so that upon dilution of the composition during cleaning, or in the cleaning environment, the protease is no longer inhibited, but rather is available to hydrolyze proteinaceous stains. Furthermore, such inhibitors must be stable enough to adequately perform their inhibitory function. Synthetic protease inhibitors or stabilizers have been disclosed for such uses, particularly in the laundry environment. For example, U.S. Patent No. 5,422,030, Panandiker et al., assigned to The Procter & Gamble Co., issued June 6, 1995, discloses aromatic borate esters to stabilize enzymes in laundry compositions. Furthermore, U.S. Patent No. 4,566,985, Bruno et al., assigned to Applied Biochemsists, Inc., issued January 28, 1986 proposes the use of benzamidine hydrochloride as an enzyme inhibitor. Such synthetic approaches to inhibition may provide longer shelf life, but may be expensive and may not improve isolation yield due to proteolysis in the fermentor. Recognizing these shortcomings, those in the art have experimented with proteinaceous protease inhibitors to stabilize enzymes in cleaning compositions. Nature provides proteinaceous protease inhibitors to regulate the protease in vivo. However, because these naturally occurring proteinaceous protease inhibitors tend to be unstable, their commercial use in the presence of proteases and cleaning and personal care carriers may be somewhat limited. Proteinaceous protease inhibitors are typically long peptides which bind to the active site of a protease and inhibit its activity. These inhibitors have typically been classified into several families (families I through IX) based on primary amino acid sequence homologies (See Laskowski et al., "Protein Inhibitors of Proteinases", Annual Review of Biochemistry. Vol. 49, pp. 593 - 626 (1980)). Included in these inhibitors are those commonly referred to as family VI inhibitors, including eglin and barley chymotrypsin inhibitor, and family III inhibitors, such as Streptomyces subtilisin inhibitor (SSI) and plasminostreptin. Such inhibitors tend to bind to certain proteases better than others. Thus it is convenient to consider the inhibitor with a specific protease in mind. For this reason, the art often discusses "protease / peptide inhibitor pairs". An example of a known protease / peptide inhibitor pair is subtilisin BPN' / SSI. See e.g., Mitsui et al., "Crystal Structure of a Bacterial Protein Proteinase Inhibitor (Streptomyces Subtilisin Inhibitor) at 2.6 A Resolution", Journal of Molecular Biology. Vol. 131, pp. 697 - 724 (1979) and Hirono et al., "Crystal Structure at 1.6 A Resolution of the Complex of Subtilisin BPN' with Streptomyces Subtilisin Inhibitor", Journal of Molecular Biology, Vol. 178, pp. 389 - 413 (1984). SSI is stable in the presence of subtilisin BPN', as long as the inhibitor is present in sufficient amounts to inhibit all protease activity. However, it has been suggested that inhibitors having high affinity for protease do not dissociate upon dilution in the wash environment. See WO 92/03529, Mikkelson et al., assigned to Novo Nordisk A S, published March 5, 1992. However, if the binding constant (K,) of an inhibitor provides for some protease activity in the cleaning composition containing the enzyme / inhibitor pair, the inhibitor, as well as enzymes in the composition, may be hydrolyzed. Therefore, it would be advantageous to find variants of SSI or other inhibitors which are suitably stable in the presence of protease as well as cleaning and personal care compositions. In addition, these inhibitors preferably have a preferred Kj for the particular protease to be inhibited. Such K j should allow for inhibition of the protease in the final composition and during its storage. However, upon dilution of the cleaning or personal care composition or during the cleaning process, the protease and inhibitor should dissociate, allowing activity of the uninhibited protease. Kojima et al., "Inhibition of Subtilisin BPN' by Reaction Site PI Mutants of Streptomyces Subtilisin Inhibitor", Journal of Biochemistry, Vol. 109, pp. 377 - 382 (1991) made and measured the K j of several SSI PI position (position 73) variants using subtilisin BPN'. As another example, Mikkelsen et al. discloses mutations in family VI inhibitors that are said to lower binding affinity. WO 93/17086, Nielsen et al, assigned to Novo Nordisk A S, published September 2, 1993, discloses mutations to plasminostreptin that are said to lower binding affinity. However, stability of such protease inhibitors has been problematic. WO 98/13387, Correa et al.. assigned to The Procter & Gamble Co., published April 2, 1998 (corresponding to U.S. Patent Application Serial No. 60/026,944) discloses variants which are disclosed as providing increased stability. Despite the variety of approaches described in the art, there is a continuing need for more stable and effective protease inhibitors useful in cleaning and personal care compositions. The present inventors have surprisingly discovered that SSI inhibitors, SSI-like inhibitors, and variants thereof are readily hydrolyzed between positions 63 and 64 corresponding to SSI during, for example, expression and / or in cleaning and personal care compositions. Accordingly, the present inventors herein provide variants of SSI inhibitors and SSI-like inhibitors which are modified, inter alia, at position 63 by a substituting amino acid residue. Such substitution imparts increased stability to the protease inhibitor. Such inhibitors are also advantageous because they bind protease at preferred levels as defined herein. The present invention therefore provides proteinaceous protease inhibitor variants having greater proteolytic stability, particularly in cleaning and personal care compositions, and lower affinity for the protease than the corresponding parent inhibitor. SUMMARY OF THE INVENTION The present invention provides variants having a modified amino acid sequence of a parent amino acid sequence, wherein the modified amino acid sequence comprises an amino acid substitution at position 63 corresponding to SSI, and wherein the parent amino acid sequence is selected from the group consisting of SSI, SSI-like inhibitors, variants of SSI, and variants of SSI-like inhibitors. Such variants are useful, for example, for inhibiting proteases, particularly during storage or expression. The present invention also relates to genes encoding such variants and cleaning and personal care compositions comprising such variants. DETAILED DESCRIPTION OF THE INVENTION The essential components of the present invention are described herein. Also included are non-limiting descriptions of various optional and preferred components useful in the embodiments of the present invention. The present invention can comprise, consist of, or consist essentially of, any of the required or optional components, ingredients, and / or limitations described herein. All percentages and ratios are calculated by weight unless otherwise indicated. All percentages are calculated based on the total composition unless otherwise indicated. Referred to herein are trade names for materials including, but not limited to, proteases and optional components. The inventors herein do not intend to be limited by materials under a certain trade name. Equivalent materials (e.g., those obtained from a different source under a different name or catalog (reference) number) to those referenced by trade name may be substituted and utilized in the compositions herein. All component, ingredient, or composition levels are in reference to the active level of that component, ingredient, or composition, and are exclusive of impurities, for example, residual solvents or by-products, which may be present in commercially available sources. All documents referred to herein, including all patents, patent applications, and printed publications, are hereby incorporated by reference in their entirety. As used herein, abbreviations will be used to describe amino acids. Table I provides a list of abbreviations used herein: Table I Definitions As used herein, the term "mutation" refers to alterations in gene sequences and amino acid sequences produced by those gene sequences. Mutations may be deletions, substitutions, or additions of amino acid residues to the wild-type or parent sequence. As used herein, the term "parent" refers to a protease, protease inhibitor, protein, or peptide, wild-type or variant, with no amino acid substitution at position 63 corresponding to SSI (i.e., the amino acid substitution at position 63 is naturally occurring). An example of one of these parents is an inhibitor known as Streptomyces Subtilisin Inhibitor (SSI) (represented by SEQ ID NO: 1). SSI is further described by Ikenaka et al.. "Amino Acid Sequence of an Alkaline Proteinase Inhibitor (Streptomyces Subtilisin Inhibitor) from Streptomyces albogriseoulus S-3253", Journal of Biochemistry. Vol. 76, pp. 1191 - 1209 (1974). As used herein, the amino acid numbering of SSI is that of Ikenaka et al. The present inventors also use a synthetic SSI gene, designed to be rich in adenine and thymine, as is B. subtilis DNA. This synthetic gene encodes four extra amino acid residues at the amino terminus of the peptide due to expression plasmid construction methods. This modified amino acid sequence, including these four additional amino acids, is represented by SEQ ID NO: 2. As used herein, the term "wild-type" refers to a protein or peptide, herein specifically a protease or protease inhibitor, produced by unmutated organisms. As used herein, the term "variant" means a protein or peptide, herein specifically a protease inhibitor or protease, having an amino acid sequence which differs from that of the parent protease inhibitor or protease, respectively. Variants of the Present Invention The present inventors have discovered variants of protease inhibitors which are more stable, for example, in vitro and in the presence of cleaning and personal care composition materials. In addition, such variants may be more stable in vivo as well, thus increasing the yield of protease from the organism. The present inventors have also discovered variants exhibiting preferred binding constants (K,), which provide for suitable inhibition of protease during growth, harvesting, purification, storage, and during the cleaning process. Such preferred binding provides for better stability and longer shelf life. The variants of the present invention have improved stability to proteases, and inhibit protease in a cleaning or personal care composition, but dissociate upon dilution in the cleaning environment. The present variants have a modified amino acid sequence of a parent amino acid sequence, wherein the modified amino acid sequence comprises an amino acid substitution at position 63 corresponding to Streptomyces subtilisin inhibitor (herein referred to as SSI), and wherein the parent amino acid sequence is selected from SSI, SSI-like inhibitors, variants of SSI, and variants of SSI-like inhibitors. The substitution at position 63 corresponding to SSI may be with any amino acid residue which imparts increased stability relative to the parent amino acid sequence. Most preferably, the substitution at position 63 corresponding to SSI is with isoleucine. Such a variant may be represented as "L63I". In describing this variant, the original amino acid occurring in the parent amino acid sequence is given first, the position number second, and the substituted amino acid third. Thus, L63I means that the leucine (L) which appeared as the sixty-third amino acid position (position 63) in the native inhibitor SSI is replaced with isoleucine (I). The position numbering corresponds to that of Ikenaka et al., supra (SEQ ID NO: 1), and ignores the four additional amino acid residues present at the amino terminus of the synthetic SSI (SEQ ID NO: 2). Such representations for other substitutions listed herein are presented in a consistent manner. The variants herein are not limited to SSI substituted at position 63. Rather, the substitution at position 63 may also be made in parent amino acid sequences (including, of course, the nucleotide sequences coding for that amino acid sequence) wherein the parent is itself a variant of SSI, an SSI-like inhibitor, or a variant of SSI-like inhibitors. The more preferred parent amino acid sequences include SSI and variants of SSI. The most preferred parent amino acid sequences are variants of SSI. Variants of SSI have been disclosed in, for example, Kojima et al., "Inhibition of Subtilisin BPN' by Reaction Site PI Mutants of Streptomyces Subtilisin Inhibitor", Journal of Biochemistry, Vol. 109, pp. 377 - 382 (1991); Tamura et al., "Mechanisms of Temporary Inhibition in Streptomyces Subtilisin Inhibitor Induced by an Amino Acid Substitution, Tryptophan 86 Replaced by Histidine", Biochemistry, Vol. 30, pp. 5275 - 5286 (1991); JO 3099-099-A, assigned to Tsumura & Co., published September 12, 1989; Mikkelsen et al., U.S. Patent No. 5,674,833, assigned to Novo Nordisk A/S, issued October 7, 1997; and WO 93/17086, Nielsen et al.. assigned to Novo Nordisk A S, published September 2, 1993. Other variants of SSI have been disclosed in U.S. Patent Application Serial No. 60/026,944, Correa et al.. corresponding to WO 98/13387, Correa et al.. assigned to The Procter & Gamble Co., published April 2, 1998, such variants herein being collectively described as "Inhibitor Group A". Preferred variants of SSI (for use as parent amino acid sequences herein) are those of Inhibitor Group A. More preferred variants which are useful as the parent amino acid sequences herein are listed in the following Tables 2 - 6. Again, all position numbering corresponds to SSI as described by Ikenaka et al. Table 2 Non-limiting Examples of Parent Amino Acid Sequences Having a Single Substitution Table 3 Non-limiting Examples of Parent Amino Acid Sequences Having Double Substitutions Table 4 Non-limiting Examples of Parent Amino Acid Sequences Having Triple Substitutions Table 5 Non-limiting Examples of Parent Amino Acid Sequences Having Quadruple Substitutions Table 6 Non-limiting Examples of Parent Amino Acid Sequences Having Quintuple Substitutions Thus, non-limiting examples of variants of the present invention may be described as Variant 1, Variant 2, etc., wherein, for example, Variant 1 may be O 00/01826 1 1 represented as L63* + D83C, wherein "*" represents any amino acid other than that originally occurring at the position corresponding to 63 in SSI, and wherein Variant 1 - 1 may be represented as L63I + D83C. Accordingly, preferred variants of the present invention are listed in the following Table 7. Even more preferred among those variants listed in Table 7 are those having isoleucine substituting at position 63. Table 7 Other preferred parent amino acid sequences herein include those comprising a substitution at position 62 corresponding to SSI. The substitution at position 62 may be any amino acid residue other than that occurring naturally in the parent (in the case of SSI, the naturally occurring amino acid residue is alanine). Preferably, the substituting amino acid at position 62 is selected from Lys, Arg, Glu, Asp, Thr, Ser, Gin, Asn, and Tφ, more preferably Lys, Arg, Glu, Asp, Thr, Ser, Gin, and Asn, still more preferably Lys, Arg, Glu, and Asp, even more preferably Lys and Arg, and most preferably Lys. Preferred parent amino acid sequences herein have a substitution at position 62 in addition to the substitutions listed in Tables 2 - 6. Examples of such parents are designated as Parent X - A62*, wherein the "X" corresponds to the parent exemplified in Tables 2 - 6. Thus, Parent 6 - A62* corresponds to A62* + M73P + D83C + S98A. Similarly, Parent 6 - A62K corresponds to A62K + M73P + D83C + S98A. Similarly, an exemplified variant of the present invention is Variant 6 - 1 - A62*, which corresponds to to A62* + L63I + M73P + D83C + S98A. Thus, Variant 6 - I - A62K corresponds to A62K + L63I + M73P + D83C + S98A. In this fashion, Table 8 lists other preferred variants of the present invention. Table 8 Non-limiting Examples of Preferred Variants of the Present Invention Other preferred parent amino acid sequences (which are variants of SSI) useful in the present invention include those having a single substitution at position 98 corresponding to SSI and those having a double substitution, one at position 62 and one at position 98. Table 9 lists preferred parent amino acid sequences in this class. Table 9 Non-limiting Examples of Parent Amino Acid Sequences The corresponding examples of variants of the present invention are listed in the following Table 10. Table 10 Non-limiting Examples of Variants of the Present Invention SSI may exist in dimeric form. Thus without being bound by theory, it is possible that stabilizing dimeric SSI provides increased protease resistance to excess protease. Preferably this stabilized dimeric SSI variant is composed of two SSI variant monomers covalently bound together. This may be by ester, amido, disulfide, or other linkages, commonly occurring in amino acids and their sidechains. Thus "covalent dimerization" and "covalent stabilization" refers to such covalently bound monomers, which form the dimer. Preferably this dimerization occurs via disulfide bonds. The variants of the present invention are meant to include those existing in dimeric form, whether by intramolecular or intermolecular forces. Other parent amino acid sequences which are useful herein include SSI-like inhibitors (often referred to as SSI-like (SIL) proteins) and variants of SSI-like inhibitors. Background information relating to SSI-like inhibitors may be found in Laskowski et al., "Protein Inhibitors of Proteases", Annual Review of Biochemistry, Vol. 49, pp. 593 - 626 (1980). Preferred SSI-like inhibitors have greater than about 50%, preferably greater than about 65%, and more preferably greater than about 70% amino acid sequence identity with SSI, preferably wherein the inhibitor may be classified as a family III inhibitor. See Laskowski et al., supra. Examples of such SSI-like inhibitors include SIL10 (the sequence of which is provided as SEQ ID NO: 4) , SIL13 (SEQ ID NO: 5), and SIL14 (SEQ ID NO: 6), each of which are further described in Terabe et al., "Three Novel Subtilisin-Trypsin Inhibitors from Streptomyces: Primary Structures and Inhibitory Properties", Journal of Biochemistry, Vol. 116, pp. 1156 - 1163 (1994), and SIL2 (the sequence of which is provided as SEQ ID NO: 9), SIL3 (SEQ ID NO: 10), and SIL4 (SEQ ID NO: 11), each of which are further described by Taguchi et al., "Comparative Studies on the Primary Structures and Inhibitory Properties of Subtilisin- trypsin Inhibitors from Streptomyces", European Journal of Biochemistry, Vol. 220, pp. 911 - 918 (1994). Two other examples of such SSI-like inhibitors include STI1 (the sequence of which is provided as SEQ ID NO: 7) and STI2 (SEQ ID NO: 8), which are further described in Strickler et al., "Two Novel Streptomyces Protein Protease Inhibitors", The Journal of Biological Chemistry. Vol. 267, No. 5, pp. 3236 - 3241 (1992). Another SSI-like inhibitor is known as plasminostreptin (the sequence of which is provided as SEQ ID NO: 12) which is further described in Sugino et al., "Plasminostreptin, a Protein Proteinase Inhibitor Produced by Streptomyces antifibrinolyticus" , The Journal of Biological Chemistry. Vol. 253, No. 5, pp. 1546 - 1555 (1978). Still another SSI-like inhibitor is SLPI (the sequence of which is provided as SEQ ID NO: 13) which is further described in Ueda et al., "A Protease Inhibitor Produced by Streptomyces lividans 66 Exhibits Inhibitory Activities Toward Both Subtilisin BPN' and Trypsin", Journal of Biochemistry, Vol. 1 12, pp. 204 - 211 (1993). Still another SSI-like inhibitor is SAC I (the sequence of which is provided as SEQ ID NO: 14) which is further described in Tanabe et al., "Primary Structure and Reactive Site of Streptoverticillium Anticoagulant (SAC), a Novel Protein Inhibitor of Blood Coagulation Produced by Streptoverticillium cinnamoneum subsp. cinnamoneum", Journal of Biochemistry. Vol. 115, pp. 752 - 761 (1994). Still another SSI-like inhibitor is SIL1 (the sequence of which is provided as SEQ ID NO: 15) which is further described in Kojima et al., "Primary Structure and Inhibitory Properties of a Proteinase Inhibitor Produced by Streptomyces cacaoϊ Biochimica et Biophysica Acta, Vol. 1207, pp. 120 - 125 (1994). Other SSI-like inhibitors are discussed in Taguchi et al., "High Frequency of SSI-Like Protease Inhibitors Among Streptomyces", Bioscience, Biotechnology, and- Biochemistry, Vol. 57, pp. 522 - 524 (1993), Taguchi et al., "Streptomyces Subtilisin Inhibitor-Like Proteins Are Distributed Widely in Streptomycetes", Applied and Environmental Microbiology, pp. 4338 - 4341 (Dec. 1993), and Suzuki et al., "Partial Amino Acid Sequence of an Alkaline Protease Inhibitor", Agricultural Biological Chemistry, Vol. 45, pp. 629 - 634 (1981). As one skilled in the art will understand, still other SSI-like inhibitors are described in the art. Variants of SSI-like inhibitors may also be utilized as parent amino acid sequences herein. Such variants include those having one or more mutations in the amino acid sequence of a selected SSI-like inhibitor as described herein, supra. Among others, all of the substitutions exemplified in the variants shown herein may also be made at corresponding positions in SSI-like inhibitors to provide a parent amino acid sequence. Other non-limiting examples of variants of SSI-like inhibitors which may be utilized as parent amino acid sequences are disclosed in Nielsen et al., WO 93/17086, assigned to Novo Nordisk A S, published September 2, 1993. As one skilled in the art will understand, position 63 (for example) of an SSI-like inhibitor, variant thereof, or variant of SSI, using its native numbering, may not correspond to position 63 of SSI. Accordingly, as is understood readily in the art, sequence numbering may need adjustment to locate the position which corresponds to that of position 63 (for example) of SSI. Sequence alignments are readily found in the references cited herein as well as other references in the art. Preferably, the present variants exhibit a Kj which allows the variant to inhibit nearly all protease (preferably greater than about 60%, more preferably about 99%) in the cleaning or personal care compositions, but dissociate from the protease upon dilution and / or during the cleaning process. For example, wherein a 2:1 stoichiometry of variant to protease is used, it is preferred that inhibitors exhibit a Kj against the protease from about 10 "12 M to about 10 "4 M, more preferably from about 10 "10 M to about 10 "6 M, and most preferably from about 10 "8 M to about 10 "7 M. Of course, should washing machine dimensions or product concentrations change, the Kj is adjusted accordingly. Prediction of a useful Kj range is readily determined by the skilled artisan without undue experimentation by considering such parameters as dilution of the composition upon use, temperature dependence of the " binding constant in relation to the temperature of cleaning method used, stoichiometry of the inhibitor to the protease, and the like. Since the variant is ultimately encoded in vivo by DNA, the DNA can be used to define the sequence of the variant. The DNA, which codes for the variant, can be used in any number of plasmids and / or expression systems, including in vitro expression systems and in vivo systems such as plants, (preferably those used in biotechnology, including tobacco, oilseed plants, such as rapeseed, soybean and the like, grain, such as maize, barley, oats, other vegetables, such as tomatoes, potatoes and the like) and microorganisms, including fungi, such as yeast, and bacteria, such as Bacillus, E. coli, and the like. Preferably the expression system is a microorganism, more preferably bacterial in nature, most preferably E. coli or Bacillus, still more preferably Bacillus. The DNA encoding the variant may be incoφorated into a plasmid or phage, active in the cell, or may be incoφorated directly into the genome of the organism which is used in cloning or expression of the variants of the invention. It should be understood that the skilled artisan, given the instruction of this invention, will appreciate that the DNA used to code for a present variant may be placed in the same plasmid, phage, or chromosome as other variants of the invention. In addition, such plasmids, phages or chromosomes may also encode proteases, including fusion proteins which include as part of the fusion protein an inhibitor and / or protease, which may or may not be inhibited by the variant of the invention. It is also well understood by the skilled artisan that the DNA described above also contemplates, and discloses the RNA transcript of the DNA. The skilled artisan can of course, without experimentation, know the RNA sequence, by inspection of the DNA sequence. The present invention also relates to genes encoding the present variants. It is also contemplated that the skilled artisan may desire to prepare antibodies to the variants of the present invention. These antibodies may be prepared using known methodologies. For example, the variants of the present invention can be injected into suitable mammalian subjects such as mice, rabbits, and the like. Suitable protocols involve repeated injection of the immunogen in the presence of adjuvants according to a schedule which boosts production of antibodies in the serum. The titers of the immune serum can readily be measured using immunoassay procedures, now standard in the art, employing the invention variants as antigens. The antisera obtained may be used directly or monoclonal antibodies may be obtained by harvesting the peripheral blood lymphocytes or the spleen of the immunized animal and immortalizing the antibody-producing cells, followed by identifying the suitable antibody producers using standard immunoassay techniques. The polyclonal or monoclonal preparations are then useful in monitoring expression of the invention, using standard test methodologies. Thus it is also envisioned that a kit may be prepared using these antibodies for one to use to determine expression levels and the like. Such antibodies can also be coupled to labels such as scintigraphic labels, e.g., technetium 99 or 1-131, or fluorescent labels, using standard coupling methods. The labeled antibodies can also be used in competitive assays, such as kinetic assays used to determine Kj. As is recognized in the art, there are occasionally errors in DNA and amino acid sequencing methods. As a result, one of ordinary skill in the art reproducing the present inventors' work from the disclosure herein can discover any sequencing errors using routine skill, and make changes as appropriate. Method of Making and Using The following examples are not meant to limit the claimed invention in any way, but rather provide the skilled artisan with guidance as to how to make and use the invention. Given the guidance of the examples, the other disclosure herein, and the information readily available to those skilled in the art, the skilled artisan is able to make and use the invention. For brevity, exhaustive recitation of the art and art known methodologies and the like are eliminated, as these are well within the purview of the skilled artisan. The variants may be prepared by mutating the nucleotide sequences that code for a parent amino acid sequence, thereby resulting in variants having modified amino acid sequences. Such methods are well-known in the art; one such method is as follows. A phagemid containing the gene corresponding to the parent amino acid sequence is used to transform Escherichia coli dut- ung- strain CJ236 and a single stranded uracil- containing DNA template is produced using the VCSM13 helper phage (Kunkel et al., "Rapid and Efficient Site-Specific Mutagenesis Without Phenotypic Selection", Methods in Enzvmology. Vol 154, pp. 367 - 382 (1987), as modified by Yuckenberg et al., "Site- Directed in vitro Mutagenesis Using Uracil-Containing DNA and Phagemid Vectors", Directed Mutagenesis - A Practical Approach. McPherson, M. J. ed., pp. 27 - 48 (1991). Primer site-directed mutagenesis modified from the method of Zoller and Smith (Zoller, M. J., and M. Smith, "Oligonucleotide - Directed Mutagenesis Using Ml 3 - Derived Vectors: An Efficient and General Procedure for the Production of Point Mutations in any Fragment of DNA", Nucleic Acids Research. Vol. 10, pp. 6487 - 6500 (1982) is used to produce all variants (essentially as presented by Yuckenberg et al., supra). Oligonucleotides are made using a 380B DNA synthesizer (Applied Biosystems Inc.). Mutagenesis reaction products are transformed into Escherichia coli strain MM294 (American Type Culture Collection E. coli 33625). All mutations are confirmed by DNA sequencing and the isolated DNA is transformed into the Bacillus subtilis expression strain PG632 (Saunders et al., "Optimization of the Signal-Sequence Cleavage Site for Secretion from Bacillus subtilis of a 34-amino acid Fragment of Human Parathyroid Hormone", Gene, Vol. 102, pp. 277 - 282 (1991) and Yang et al., "Cloning of the Neutral Protease Gene of Bacillus subtilis and the Use of the Cloned Gene to Create an in vitro - Derived Deletion Mutation", Journal of Bacteriology. Vol. 160, pp. 15 - 21 (1984). Variant preparations are made as follows. Bacillus subtilis cells containing the plasmid of interest are cultured in medium with 20 g/1 tryptone, 20 g/1 yeast extract, and 5 g/1 of sodium chloride supplemented with 1.25% maltrin Ml 00 (Grain Processing Coφoration, Muscatine, IA), 100 mM HEPES pH 7.5, 80 μM MnCl 2 , and 50 μM kanamycin. The cultures are incubated for 24 hours at 37°C. The variant is purified by first removing the cells by centrifugation. The pH is then dropped to about 4 by adding 1 N HC1. The insoluble material is pelleted by centrifugation. Typically, the variant is found in the supernatant. The supernatant is then dialyzed versus 20 mM sodium acetate pH 4. The variant typically precipitates at this step. Both precipitates are resuspended in Tris base and assayed for the inhibition of a Y217L derivative of subtilisin BPN'. In some instances, the variant remains soluble through these precipitation steps. In such a case, the soluble fraction is separated on an S Sepharose column, run in 20 mM sodium acetate pH 4. The sample is eluted with increasing concentrations of sodium chloride and assayed for protease inhibition. In all cases, variant-containing fractions are dialyzed against 1 mM Tris pH 8.0 before use. Characterization of the Variants of the Present Invention SSI inhibits, inter alia, subtilisin BPN' and a Y217L variant of subtilisin BPN'. Inhibition activity of the present variants is measured as follows, using SSI as an example. SSI is mixed with protease and incubated for fifteen minutes at room temperature in the presence of 0.1 M Tris, pH 8.6, 10 mM CaCl 2 . Protease activity is then measured using the method of DelMar et al., Analytical Biochemistry, Vol. 99, pp. 316-320 (1979). Addition of 10 μL of N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (20 mg/mL) begins the reaction. The reaction rate is measured by the increase in absorbance at 410 nm which indicates inhibition of the protease. The inhibitory properties of the variants of the present invention are similarly determined. Because it is desirable to incoφorate a variant of the present invention with a protease into cleaning or personal care compositions (suitable proteases are described herein infra), the stability in the product environment is also tested. The stability of a variant may be monitored by measuring protease activity over time. If the variant is stable, the level of protease activity will be constant. However, if a variant is destroyed, the protease activity will rise. In this example, variants are mixed with 1.1 nmol of a subtilisin BPN' variant having a Y217L substitution. Water is added so that the volumes of all samples are the same. A complex is allowed to form over ten minutes in a liquid detergent composition made according to the following formula: This composition constitutes one-third of the total sample volume. 15 μL of sample is mixed with 975 μL of 0.1 M Tris HC1, pH 8.6, 0.01 M CaCl2- This dilution is incubated for thirty minutes at room temperature. After incubation, substrate is added, and the amount of protease is measured. Degradation of the variant is detected by increase in protease activity over several weeks. Such degradation may be directly compared to that of, for example, SSI. The Kj of a variant is determined as follows. The variant and 600 μg/mL succinyl-Ala-Ala-Pro-Phe-p-nitroanilide are mixed in 990μL of a 50 mM Tris pH 8 solution. The reaction is started by the addition of a selected protease (suitable proteases are described herein infra). The hydrolysis rate is followed over twenty minutes. A constant rate is observed over the last ten to fifteen minutes. This rate, compared to the rate in the absence of variant, is used to calculate the K, according to the equations of Goldstein, "The Mechanism of Enzyme-Inhibitor-Substrate Reactions", Journal of General Physiology. Vol. 27, pp. 529 - 580 (1944). Cleaning Compositions of the Present Invention In another embodiment of the present invention, an effective amount of one or more of the present variants is included in cleaning compositions useful for cleaning a variety of surfaces in need of peptide stain removal. Such cleaning compositions include, but are not limited to, fabric cleaning compositions, hard surface cleansing compositions, light duty cleaning compositions including dish cleansing compositions, and automatic dishwasher detergent compositions. The cleaning compositions herein comprise an effective amount of one or more variants of the present invention and a cleaning composition carrier, which carrier includes a protease. As used herein, "effective amount of variant", or the like, refers to the quantity of variant necessary to achieve the proteolytic activity necessary in the specific cleaning composition. Such effective amounts are readily ascertained by one of ordinary skill in the art and is based on many factors, such as the particular variant used, the cleaning application, the specific composition of the cleaning composition, and whether a liquid or dry (e.g., granular, bar) composition is desired, and the like. Preferably, the cleaning compositions comprise from about 0.0001% to about 10%, more preferably from about 0.001% to about 1%, and most preferably from about 0.01% to about 0.1%) of one or more variants of the present invention. Several examples of various cleaning compositions wherein the variants may be employed are discussed in further detail below. The present variants are useful in cleaning compositions to inhibit a protease therein during storage, thereby protecting the protease from autolysis or hydrolysis from other sources such as additional enzymes present in the composition. Accordingly, an essential ingredient in the present cleaning compositions is a protease of which the present variants inhibit. The protease may be of animal, plant or, preferably, microorganism origin. Preferred proteases include those for which SSI is an inhibitor. Such proteases include, for example, those produced by Bacillus alcalophilus, Bacillus amyloliquefaciens, Bacillus amylosaccharicus, Bacillus licheniformis, Bacillus lentus, and Bacillus subtilis microorganisms. Among such proteases the preferred include, for example, subtilisin BPN, subtilisin BPN', subtilisin Carlsberg, subtilisin DY, subtilisin 309, proteinase K, and thermitase, including A S Alcalase® (Novo Industries, Copenhagen, Denmark), Esperase® (Novo Industries), Savinase® (Novo Industries), Maxatase® (Gist-Brocades, Delft, Netherlands), Maxacal® (Gist-Brocades), Maxapem 15® (Gist-Brocades), and variants of the foregoing. Especially preferred proteases for use herein include those obtained from Bacillus amyloliquefaciens and variants thereof. The most preferred wild-type protease is subtilisin BPN'. Variants of subtilisin BPN', hereinafter collectively referred to as "Protease Group A", are useful as the proteases herein and are disclosed in U.S. Patent No. 5,030,378, Venegas. July 9, 1991 as characterized by the subtilisin BPN' amino acid sequence (the sequence of which is represented as SEQ ID: NO 3) with the following mutations: (a) Gly at position 166 is substituted with Asn, Ser, Lys, Arg, His,. Gin, Ala or Glu; Gly at position 169 is substituted with Ser; and Met at position 222 is . substituted with Gin, Phe, His, Asn, Glu, Ala or Thr; or (b) Gly at position 160 is substituted with Ala, and Met at position 222 is substituted with Ala. Additional variants of subtilisin BPN', hereinafter collectively referred to as "Protease Group B", are useful as the proteases herein and are disclosed in European Patent EP-B-251 ,446, assigned to Genencor International, Inc., published January 7, 1988, and granted December 28, 1994, as characterized by the wild-type BPN' amino acid sequence with mutations at one or more of the following positions: Tyr21, Thr22, Ser24, Asp36, Ala45, Ala48, Ser49, Met50, His67, Ser87, Lys94, Val95, Gly97, SerlOl, Gly 102, Gly 103, Ilel07, Gly 110, Met 124, Glyl27, Glyl28, Prol29, Leul35, Lysl70, Tyrl71, Prol72, Aspl97, Metl99, Ser204, Lys213, Tyr214, Gly215, and Ser221 ; or two or more of the positions listed above combined with Asp32, Ser33, Tyrl04, Alal52, Asnl55, Glul56, Glyl66, Glyl69, Phel89, Tyr217, and Met222. Another preferred subtilisin BPN' variant useful as the proteases herein are hereinafter collectively referred to as "Protease Group C", and are described in WO 95/10615, assigned to Genencor International Inc., published April 20, 1995 as characterized by the wild-type subtilisin BPN' amino acid sequence with a mutation to position Asn76, in combination with mutations in one or more other positions selected from the group consisting of Asp99, SerlOl, Glnl03, Tyrl04, Serl05, Ilel07, Asnl09, Asnl23, Leul26, Glyl27, Glyl28, Leul35, Glul56, Glyl66, Glul95, Aspl97, Ser204, Gln206, Pro210, Ala216, Tyr217, Asn218, Met222, Ser260, Lys265, and Ala274. Other preferred subtilisin BPN' variants useful as the proteases herein, collectively referred to as "Protease Group D", are described in U.S. Patent No. 4,760,025, Estell. et al.. July 26, 1988, as characterized by the wild-type subtilisin BPN' amino acid sequence with mutations to one or more amino acid positions selected from the group consisting of Asp32, Ser33, His64, Tyrl04, Asnl55, Glul56, Gly 166, Gly 169, Phel89, Tyr217, and Met222. The more preferred proteases as used herein are selected from the group consisting of Alcalase®, subtilsin BPN', Protease Group A, Protease Group B, Protease Group C, and Protease Group D. The most preferred protease is selected from Protease Group O. The present compositions comprise from about 0.0001% to about 1%, preferably from about 0.0005% to about 0.2%, most preferably from about 0.002% to about 0.1%, by weight of the composition, of active protease. Mixtures of protease may also be included. Of course, the weight percent of protease in the cleaning composition will vary depending on the water content, builder content, and the like of the finished composition. For example, it is preferred that in a granular detergent, from about 0.064 mg / g to about 0.64 mg / g of protease in the composition is desirable. In a preferred embodiment, the preferred molar ratio of variant to protease (variant to protease ratio) in cleaning compositions is from about 3:1 to about 1:1, more preferably from about 3:1 to about 1.5:1, and most preferably about 2:1. In addition to the present variants, the present cleaning compositions further comprise a cleaning composition carrier comprising one or more cleaning composition materials compatible with the variant and / or the protease. The term "cleaning composition material", as used herein, means any material selected for the particular type of cleaning composition desired and the form of the product (e.g., liquid, granule, bar, spray, stick, paste, gel), which materials are also compatible with the variant used in the composition. The specific selection of cleaning composition materials is readily made by considering the material to be cleaned, the desired form of the composition for the cleaning condition during use. The term "compatible", as used herein, means the cleaning composition materials do not reduce the inhibitory activity of the variant and / or the proteolytic activity of the protease to such an extent that the protease is not effective as desired during normal use situations. Specific cleaning composition materials are exemplified in detail hereinafter. The variants of the present invention may be used in a variety of detergent compositions where high sudsing and good cleansing activity is desired. Thus, the variants can be used with various conventional ingredients to provide fully-formulated hard-surface cleaners, dishwashing compositions, fabric laundering compositions, and the like. Such compositions can be in the form of liquids, granules, bars, and the like. Such compositions can be formulated as "concentrated" detergents which contain as much as from about 30% to about 60% by weight of surfactants. The cleaning compositions herein may optionally, and preferably, contain various surfactants (e.g., anionic, nonionic, or zwitterionic surfactants). Such surfactants are typically present at levels of from about 5% to about 35% of the compositions. Nonlimiting examples of surfactants useful herein include the conventional C π - Cjs alkyl benzene sulfonates and primary and random alkyl sulfates, the Cio-Cjg secondary (2,3) alkyl sulfates of the formulas CH 3 (CH 2 ) x (CHOSO 3 )-M+)CH 3 and CH 3 (CH 2 ) y (CHOSO 3 -M + ) CH 2 CH 3 wherein x and (y+1) are integers of at least about 7, preferably at least about 9, and M is a water-solubilizing cation, especially sodium, the Cjo-Cjg alkyl alkoxy sulfates (especially EO 1-5 ethoxy sulfates), Cio-Cjg alkyl alkoxy carboxylates (especially the EO 1-5 ethoxycarboxylates), the CjQ-Cig alkyl polyglycosides, and their corresponding sulfated polyglycosides, C j -C \ g -sulfonated fatty acid esters, Cι -Cι g alkyl and alkyl phenol alkoxylates (especially ethoxylates and mixed ethoxy /propoxy), C j -Cιg betaines and sulfobetaines ("sultaines"), Cjo-Cj amine oxides, and the like. The alkyl alkoxy sulfates (AES) and alkyl alkoxy carboxylates (AEC) are preferred herein. The use of such surfactants in combination with the amine oxide and / or betaine or sultaine surfactants is also preferred, depending on the desires of the formulator. Other conventional useful surfactants are listed in- standard texts. Particularly useful surfactants include the Cjo-Ci g N-methyl glucamides disclosed in U.S. Patent No. 5, 194,639, Connor et al.. issued March 16, 1993. A wide variety of other ingredients useful in the present cleaning compositions include, for example, other active ingredients, carriers, hydrotropes, processing aids, dyes or pigments, and solvents for liquid formulations. If an additional increment of sudsing is desired, suds boosters such as the Cjo-Ci g alkolamides can be incoφorated into the compositions, typically at about 1% to about 10% levels. The C10-C14 monoethanol and diethanol amides illustrate a typical class of such suds boosters. Use of such suds boosters with high sudsing adjunct surfactants such as the amine oxides, betaines and sultaines noted above is also advantageous. If desired, soluble magnesium salts such as MgCl , MgSO and the like, can be added at levels of, typically, from about 0.1% to about 2%, to provide additional sudsing. The liquid detergent compositions herein may contain water and other solvents as carriers. Low molecular weight primary or secondary alcohols exemplified by methanol, ethanol, propanol, and wo-propanol are suitable. Monohydric alcohols are preferred for solubilizing surfactants, but polyols such as those containing from about 2 to about 6 carbon atoms and from about 2 to about 6 hydroxy groups (e.g., 1 ,3-propanediol, ethylene glycol, glycerine, and 1,2-propanediol) can also be used. The compositions may contain from about 5% to about 90%, typically from about 10% to about 50% of such carriers. The detergent compositions herein will preferably be formulated such that during use in aqueous cleaning operations, the wash water will have a pH between about 6.8 and about 11. Finished products are typically formulated at this range. Techniques for controlling pH at recommended usage levels include the use of, for example, buffers, alkalis, and acids. Such techniques are well known to those skilled in the art. When formulating the hard surface cleaning compositions and fabric cleaning compositions of the present invention, the formulator may wish to employ various builders at levels from about 5% to about 50% by weight. Typical builders include the 1- 10 micron zeolites, polycarboxylates such as citrate and oxydisuccinates, layered silicates, phosphates, and the like. Other conventional builders are listed in standard formularies. Likewise, the formulator may wish to employ various additional enzymes, such as cellulases, lipases, amylases and proteases in such compositions, typically at levels of from about 0.001% to about 1% by weight. Various detersive and fabric care enzymes are well-known in the laundry detergent art. Various bleaching compounds, such as the percarbonates, perborates and the like, can be used in such compositions, typically at levels from about 1% to about 15% by weight. If desired, such compositions can also contain bleach activators such as tetraacetyl ethylenediamine, nonanoyloxybenzene sulfonate, and the like, which are also known in the art. Usage levels typically range from about 1% to about 10% by weight. Soil release agents, especially of the anionic oligoester type, chelating agents, especially the aminophosphonates and ethylenediaminedisuccinates, clay soil removal agents, especially ethoxylated tetraethylene pentamine, dispersing agents, especially polyacrylates and polyasparatates, brighteners, especially anionic brighteners, suds suppressors, especially silicones and secondary alcohols, fabric softeners, especially smectite clays, and the like can all be used in such compositions at levels ranging from about 1% to about 35% by weight. Standard formularies and published patents contain multiple, detailed descriptions of such conventional materials. Enzyme stabilizers may also be used in the cleaning compositions. Such enzyme stabilizers include propylene glycol (preferably from about 1% to about 10%), sodium formate (preferably from about 0.1%) to about 1%) and calcium formate (preferably from about 0.1% to about 1%). Other useful cleaning composition materials include clay soil removal agents, dispersing agents, brighteners, suds suppressors, and fabric softeners. The present variants are useful in hard surface cleaning compositions. As used herein "hard surface cleaning composition" refers to liquid and granular detergent compositions for cleaning hard surfaces such as floors, walls, bathroom tile, and the like. Hard surface cleaning compositions typically comprise a surfactant and a water-soluble sequestering builder. In certain specialized products such as spray window cleaners, however, the surfactants are sometimes not used since they may produce a filmy and / or streaky residue on the glass surface. The surfactant component, when present, may comprise as little as 0.1 % of the compositions herein, but typically the compositions will contain from about 0.25% to about 10%), more preferably from about 1% to about 5% of surfactant. Typically the compositions will contain from about 0.5%) to about 50%) of a detergency builder, preferably from about 1% to about 10%>. Preferably the pH should be in the range of from about 7 to about 12. Conventional pH adjustment agents such as sodium hydroxide, sodium carbonate or hydrochloric acid can be used if adjustment is necessary. Solvents may be included in the compositions. Useful solvents include, but are not limited to, glycol ethers such as diethyleneglycol monohexyl ether, diethyleneglycol monobutyl ether, ethyleneglycol monobutyl ether, ethyleneglycol monohexyl ether, propyleneglycol monobutyl ether, dipropyleneglycol monobutyl ether, and diols such as 2,2,4-trimethyl-l,3-pentanediol and 2-ethyl-l,3-hexanediol. When used, such solvents are typically present at levels of from about 0.5% to about 15%, more preferably from about 3% to about 11%. Additionally, highly volatile solvents such as /.so-propanol or ethanol can be used in the present compositions to facilitate faster evaporation of the composition from surfaces when the surface is not rinsed after "full strength" application of the composition to the surface. When used, volatile solvents are typically present at levels of from about 2% to about 12% in the compositions. The present variants are also useful for inclusion in the cleaning compositions described in the following: Provisional U.S. Patent Application Serial No. 60/079,477, Rubingh et al„ filed March 26, 1998; Provisional U.S. Patent Application Serial No. 60/079,397, Rubingh et al. filed March 26, 1998; U.S. Patent Application Serial No. 09/048,174, Weisgerber et al.. filed March 26, 1998; and U.S. Patent Application Serial No. 09/088912, claiming priority to U.S. Patent Application Serial No. 09/048,174, Weisgerber et al.. filed June 2, 1998. Hard surface cleaning compositions of the present invention are illustrated by the- following examples. Examples 1 - 6 Liquid Hard Surface Cleaning Compositions All formulas are adjusted to pH 7. In Examples 1 - 6, the variants recited in Tables 7, 8, and 10, and the preferred variants cited herein, among others, are substituted for Variant 6 - 1, with substantially similar results. In another embodiment of the present invention, dishwashing compositions comprise one or more variants of the present invention. As used herein, "dishwashing composition" refers to all forms of compositions for cleaning dishes including, but not limited to, granular and liquid forms. Dishwashing compositions of the present invention are illustrated by the following examples. Examples 7 - 10 Liquid Dish Detergent All formulas are adjusted to pH 7. In Examples 7 - 10, the variants recited in Tables 7, 8, and 10, and the preferred variants cited herein, among others, are substituted for Variant 7 - I - A62K, with substantially similar results. Liquid fabric cleaning compositions of the present invention are illustrated by the following examples. Examples 11 - 13 Liquid Fabric Cleaning Compositions In Examples 11 - 13, the variants recited in Tables 7, 8, and 10, and the preferred variants cited herein, among others, are substituted for Variant 2 - 1, with substantially similar results. Personal Care Compositions The present variants are also suited for use in personal care compositions selected from, for example, leave-on and rinse-off hair conditioners, shampoos, leave-on and rinse-off acne compositions, facial milks and conditioners, shower gels, soaps, foaming and non-foaming facial cleansers, cosmetics, hand, facial, and body lotions and moisturizers, leave-on facial moisturizers, cosmetic and cleansing wipes, oral care compositions, and contact lens care compositions. The present personal care compositions comprise and effective amount of one or more variants of the present invention and a personal care carrier, which personal care carrier includes a protease. Effective amounts of variants, including preferred limitations, are described herein with respect to cleaning compositions. Suitable proteases, including those which are preferable, are described herein with respect to cleaning compositions. To illustrate, the present variants are suitable for inclusion, along with a protease, in the compositions described in the following references: U.S. Pat. No. 5,641,479, Linares et al.. issued June 24, 1997 (skin cleansers); U.S. Pat. No. 5,599,549, Wivell et aL, issued February 4, 1997 (skin cleansers); U.S. Pat. No. 5,585,104, Ha et al.. issued December 17, 1996 (skin cleansers); U.S. Pat. No. 5,540,852, Kefauver et al.. issued July 30, 1996 (skin cleansers); U.S. Pat. No. 5,510,050, Dunbar et al.. issued April 23, 1996 (skin cleansers); U.S. Pat. No. 5,612,324, Guang Lin et al.. issued March 18, 1997 (anti- acne preparations); U.S. Pat. No. 5,587,176, Warren et al, issued December 24, 1996 (anti-acne preparations); U.S. Pat. No. 5,549,888, Venkateswaran, issued August 27, 1996 (anti-acne preparations); U.S. Pat. No. 5,470,884, Corless et al., issued November 28, 1995 (anti-acne preparations); U.S. Pat. No. 5,650,384, Gordon et al., issued July 22, 1997 (shower gels); U.S. Pat. No. 5,607,678, Moore et al.. issued March 4, 1997 (shower gels); U.S. Pat. No. 5,624,666, Coffindaffer et al.. issued April 29, 1997 (hair conditioners and / or shampoos); U.S. Pat. No. 5,618,524, Bolich et al.. issued April 8, 1997 (hair conditioners and / or shampoos); U.S. Pat. No. 5,612,301, Inman, issued March 18, 1997 (hair conditioners and / or shampoos); U.S. Pat. No. 5,573,709, Wells, issued November 12, 1996 (hair conditioners ' and / or shampoos); U.S. Pat. No. 5,482,703, Pings, issued January 9, 1996 (hair conditioners and / or shampoos); U.S. Pat. No. Re. 34,584, Grote et al.. Reissued April 12, 1994 (hair conditioners and / or shampoos); U.S. Pat. No. 5,641,493, Date et al.. issued June 24, 1997 (cosmetics); U.S. Pat. No. 5,605,894, Blank et al.. issued February 25, 1997 (cosmetics); U.S. Pat. No. 5,585,090, Yoshioka et al.. issued December 17, 1996 (cosmetics); U.S. Pat. No. 4,939,179, Cheney et al.. issued July 3, 1990 (hand, face, and / or body lotions); U.S. Pat. No. 5,607,980, McAtee et al.. issued March 4, 1997 (hand, face, and / or body lotions); U.S. Pat. No. 4,045,364, Richter et al.. issued August 30, 1977 (cosmetic and cleansing wipes); European Patent Application, EP 0 619 074, Touchet et al.. published October 12, 1994 (cosmetic and cleansing wipes); U.S. Pat. No. 4,975,217, Brown-Skrobot et al., - issued December 4, 1990 (cosmetic and cleansing wipes); U.S. Pat. No. 5,096,700, Seibel. issued March 17, 1992 (oral cleaning compositions); U.S. Pat. No. 5,028,414, Sampathkumar. issued July 2, 1991 (oral cleaning compositions); U.S. Pat. No. 5,028,415, Benedict et al.. issued July 2, 1991 (oral cleaning compositions); U.S. Pat. No. 5,028,415, Benedict et al.. issued July 2, 1991 (oral cleaning compositions); U.S. Pat. No. 4,863,627, Davies et al.. September 5, 1989 (contact lens cleaning solutions); U.S. Pat. No. Re. 32,672, Huth et al. reissued May 24, 1988 (contact lens cleaning solutions); and U.S. Pat. No. 4,609,493, Schafer. issued September 2, 1986 (contact lens cleaning solutions). The present variants are also useful for inclusion in the personal care compositions described in the following: Provisional U.S. Patent Application Serial No. 60/079,477, Rubingh et al. filed March 26, 1998; Provisional U.S. Patent Application Serial No. 60/079,397, Rubingh et al.. filed March 26, 1998; U.S. Patent Application Serial No. 09/048,174, Weisgerber et al. filed March 26, 1998; and U.S. Patent Application Serial No. 09/088912, claiming priority to U.S. Patent Application Serial No. 09/048,174, Weisgerber et al.. filed June 2, 1998. In a preferred embodiment, the preferred molar ratio of variant to protease (variant to protease ratio) in personal care compositions is from about 3 : 1 to about 1 :1, more preferably from about 3:1 to about 1.5:1, and most preferably about 2:1. To further illustrate oral cleaning compositions of the present invention, one or more variants of the present invention and one or more proteases are included in compositions useful for removing proteinaceous stains from teeth or dentures. As used herein, "oral cleaning compositions" refers to dentifrices, toothpastes, toothgels, toothpowders, mouthwashes, mouth sprays, mouth gels, chewing gums, lozenges, sachets, tablets, biogels, prophylaxis pastes, dental treatment solutions, and the like. Preferably, the oral cleaning compositions comprise from about 0.0001% to about 20% of one or more variants of the present invention, together with a protease, more preferably from about 0.001% to about 10%>, more preferably still from about 0.01% to about 5%, by weight of the composition, and a personal care carrier. Typically, the personal care carrier components of the oral cleaning components of the oral cleaning compositions will generally comprise from about 50% to about 99.99%), preferably from about 65% to about 99.99%), more preferably from about 65%> to about 99%, by weight of the composition. The personal care carrier components and optional components which may be included in the oral cleaning compositions of the present invention are well known to those skilled in the art. A wide variety of composition types, carrier components and optional components useful in the oral cleaning compositions are disclosed in the references cited hereinabove. In another embodiment of the present invention, denture cleaning compositions for cleaning dentures outside of the oral cavity comprise one or more variants of the present invention. Such denture cleaning compositions comprise one or more of the variants of the present invention together with a protease, preferably from about 0.0001%) to about 50%), more preferably from about 0.001% to about 35%, more preferably still from about 0.01% to about 20%, by weight of the composition, and a personal care carrier. Various denture cleansing composition formats such as effervescent tablets and the like are well known in the art (see, e.g., U.S. Pat. No. 5,055,305, Young), and are generally appropriate for incoφoration of one or more of the variants for removing proteinaceous stains from dentures. In another embodiment of the present invention, contact lens cleaning compositions comprise one or more variants of the present invention. Such contact lens cleaning compositions comprise one or more of the variants, preferably from about ' 0.01% to about 50%) of one or more of the variants, more preferably from about 0.01% to about 20%), more preferably still from about 1% to about 5%>, by weight of the composition, and a personal care carrier. Various contact lens cleaning composition formats such as tablets, liquids and the like are well known in the art and are generally appropriate for incoφoration of one or more variants of the present invention for removing proteinaceous stains from contact lenses. The contact lens cleaning composition embodiment of the present invention is illustrated by Examples 14 - 17. Examples 14-17 Contact Lens Cleaning Solution In Examples 14 - 17, the variants recited in Tables 7, 8, and 10, and the preferred variants cited herein, among others, are substituted for Variant 9-1 with substantially similar results. Examples 18-21 illustrate the use of the present variants in bodywash products: Examples 18-21 Bodywash Products In Examples 18 - 21, the variants recited in Tables 7, 8, and 10, and the preferred variants cited herein, among others, are substituted for Variant 14 - 1, with substantially similar results. Examples 18 - 21 illustrate the use of the present variants in facewash products: EXAMPLES 22 - 25 Facewash Products In Examples 22 - 25, the variants recited in Tables 7, 8, and 10, and the preferred variants cited herein, among others, are substituted for Variant 24 - 1, with substantially similar results. Examples 26 - 27 illustrate the use of the present variants in leave-on skin moisturizing compositions: EXAMPLES 26 - 27 Leave-on Skin Moisturizing Composition In Examples 26 - 27, the variants recited in Tables 7, 8, and 10, and the preferred variants cited herein, among others, are substituted for Variant 13 - 1 with substantially similar results. Example 28 illustrates the use of the present variants in cleansing wipe commpositions: EXAMPLE 28 Cleansing Wipe Composition The above composition is impregnated onto a woven absorbent sheet comprised- of cellulose and / or polyester at about 150%, by weight of the absorbent sheet. In Example 28, the variants recited in Tables 7, 8, and 10, and the preferred variants cited herein, among others, are substituted for Variant 20 - 1 with substantially similar results.

Claims: What is claimed is: 1. A variant characterized by a modified amino acid sequence of a parent amino acid sequence, wherein the modified amino acid sequence is characterized by an amino. acid substitution at position 63 corresponding to SSI, and wherein the parent amino acid sequence is selected from the group consisting of SSI, SSI-like inhibitors, variants of SSI, and variants of SSI-like inhibitors. 2. A variant according to Claim 1 wherein the amino acid substitution at position 63 corresponding to SSI is with isoleucine. 3. A variant according to any of the preceding claims wherein the parent amino acid sequence is selected from the group consisting of SSI and variants of SSI. 4. A variant according to any of the preceding claims which exhibits a K, such that the variant: (a) inhibits a protease in a composition comprising the variant and the protease; and (b) dissociates from the protease upon dilution. 5. A variant according to any of the preceding claims which exhibits a K, is from about 10 12 M to about 10 "4 M. 6. A variant according to any of the preceding claims selected from the group consisting of: (a) L63I + D83C; (b) L63I + M73D; (c) L63I + M73D + D83C; (d) L63I + M73P + D83C; (e) L63I + M70Q + D83C; (f) L63I + M70Q + M73P + V74F + D83C; (g) L63I + M70Q + M73P + V74W + D83C; (h) L63I + M70Q + M73P + D83C + S98A; (i) L63I + G47D + M73P + V74F + D83C; 0) L63I + G47D + M73P + V74W + D83C; (k) L63I + G47D + M73P + D83C + S98A; (1) L63I + G47D + M70Q + M73P + V74F + D83C; (m) L63I + G47D + M70Q + M73P + V74W + D83C; (n) L63I + G47D + M73P + V74F + D83C + S98A; (o) L63I + G47D + M73P + V74W + D83C + S98A; (p) A62* + L63I + D83C; (q) A62* + L63I + M73D; (r) A62* + L63I + M73D + D83C; (s) A62* + L63I + M73P + D83C; (t) A62* + L63I + M70Q + D83C; (u) A62* + L63I + M73P + D83C + S98A (v) A62* + L63I + M73P + Y75A + D83C; (w) A62* + L63I + M73P + D83C + S98V; (x) A62* + L63I + M70Q + M73P + D83C; (y) A62* + L63I + M73P + V74A + D83C; (z) A62* + L63I + M73P + V74F + D83C; (aa) A62* + L63I + M70Q + D83C + S98A; (bb) A62* + L63I + G47D + M70Q + D83C; (cc) A62* + L63I + G47D + D83C + S98A; (dd) A62* + L63I + G47D + M73P + D83C; (ee) A62* + L63I + G47D + M73D + D83C; (ff) A62* + L63I + M70Q + M73P + V74F + D83C; (gg) A62* + L63I + M70Q + M73P + V74W + D83C; (hh) A62* + L63I + M70Q + M73P + D83C + S98A; (ii) A62* + L63I + G47D + M73P + V74F + D83C; (jj) A62* + L63I + G47D + M73P + V74W + D83C; (kk) A62* + L63I + G47D + M73P + D83C + S98A; (11) A62* + L63I + G47D + M70Q + M73P + V74F + D83C; (mm) A62* + L63I + G47D + M70Q + M73P + V74W + D83C; (nn) A62* + L63I + G47D + M73P + V74F + D83C + S98A; (oo) A62* + L63I + G47D + M73P + V74W + D83C + S98A; (pp) L63I + A62K + S98Q; (qq) L63I + A62K + S98D; (rr) L63I + A62K + S98E; (ss) L63I + A62R + S98Q; (tt) L63I + A62R + S98D; (uu) L63I + A62R + S98E; (w) L63I + S98A; (ww) L63I + M73P + D83C + S98D; (xx) L63I + M73P + D83C + S98E; (yy) L63I + M73P + S98D; (zz) L63I + M73P + S98E; (aaa) L63I + M73P + S98A; (bbb) A62K + L63I + M73P + D83C + S98D; (ccc) A62R + L63I + M73P + D83C + S98D; (ddd) A62K + L63I + M73P + D83C + S98E; (eee) A62R + L63I + M73P + D83C + S98E; (ffi) A62K + L63I + M73P + S98A; (ggg) A62R + L63I + M73P + S98A; (hhh) L63I + G47D + M73P + D83C + S98D; (iii) L63I + G47D + M73P + D83C + S98E; and (!) L63I + M73P. 7. A variant according to any of the preceding claims selected from the group consisting of: (a) A62K + L63I + M73P 4- D83C + S98Q; (b) A62K + L63I + M73P + D83C + S98D; (c) A62K + L63I + M73P + D83C + S98E; (d) A62K + L63I + S98Q; (e) A62K + L63I + S98D; (f) A62K + L63I + S98E; (g) A62R + L63I + M73P + D83C + S98Q; (h) A62R + L63I + M73P + D83C + S98D; (i) A62R + L63I + M73P + D83C + S98E; (j) L63I + M73P + D83C + S98A. (k) A62R + L63I + S98Q; (1) A62R + L63I + S98D; (m) A62R -1- L63I + S98E; (n) L63I + S98A; (o) A62K + L63I + M73P + D83C + S98D; (p) A62R + L63I + M73P + D83C + S98D; (q) A62K + L63I + M73P + D83C + S98E; (r) A62R + L63I + M73P + D83C + S98E; (s) A62K + L63I + M73P + S98A; and (t) A62R + L63I + M73P + S98A. 8. A mutant gene encoding a variant according to any of the preceding claims. 9. A composition comprising a variant according to any of the preceding claims and a carrier selected from the group consisting of a cleaning composition carrier and a personal care carrier. 10. A composition according to Claim 9 wherein the variant to protease ratio is from about 3:1 to about 1:1.

Inventors: BAUER MARK DONALD, CORREA PAUL ELLIOTT, RUBINGH DONN NELTON, SAUNDERS CHARLES WINSTON, SUN YIPING, BAUER, MARK, DONALD, CORREA, PAUL, ELLIOTT, RUBINGH, DONN, NELTON, SAUNDERS, CHARLES, WINSTON, SUN, YIPING
Applicants: BAUER MARK DONALD, CORREA PAUL ELLIOTT, PROCTER & GAMBLE, RUBINGH DONN NELTON, SAUNDERS CHARLES WINSTON, SUN YIPING, BAUER, MARK, DONALD, CORREA, PAUL, ELLIOTT, RUBINGH, DONN, NELTON, SAUNDERS, CHARLES, WINSTON, SUN, YIPING, THE PROCTER & GAMBLE COMPANY
Application year: 1999
Main classification: C12N15
IPC codes: C07K14, C11D3, C12N15